Immunovaccine Chief Medical Officer Dr. Gabriela Rosu to Present at the Oncology Meeting Innovations (OMI) Annual Summit on H...
March 08 2018 - 5:05PM
Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage
immuno-oncology company, today announced that its Chief Medical
Officer, Gabriela Nicola Rosu, MD, will conduct an oral
presentation at the fifth annual Summit On Hematologic
Malignancies. The conference is taking place at the Fairmount
Chateau Whistler in Whistler, British Columbia, from March 14 –
March 18, 2017.
Dr. Rosu will present an overview of Immunovaccine’s lead
candidate, DPX-Survivac, including the clinical strategy for
evaluating this program in diffuse large B cell Lymphoma. Details
of Dr. Rosu’s presentation are as follows:
|
|
|
Name: |
|
DPX Survivac - a Novel,
Long-lasting, T Cell ActivatingImmunotherapy |
Date: |
|
Saturday, March 17,
2018 |
Time: |
|
11:45 am PT |
Location: |
|
The MacDonald Room,
Fairmount Chateau Whistler, 4599Chateau Blvd., Whistler, British
Columbia V0N 1B4 Canada |
|
|
|
The conference, sponsored by Oncology Meeting Innovations, is
designed to engage top researchers and practicing clinicians to
discuss emerging clinical data, current treatment options, and the
future treatment landscape for hematological malignancies.
Indications covered at the meeting will include Chronic Lymphocytic
Leukemia, Multiple Myeloma, aggressive and indolent Lymphomas and
Acute Leukemias.
Oncology Meeting Innovations (OMI) is part of DAVA Oncology, LP
and provides premier oncology meetings for industry leaders to
connect and continually improve oncology patient care.
About DPX-SurvivacDPX-Survivac consists of
survivin-based peptide antigens formulated in the Company’s
proprietary DepoVax™ delivery platform. DPX-Survivac is thought to
work by eliciting a cytotoxic T cell immune response against cells
presenting survivin peptides. Survivin, recognized by the National
Cancer Institute (NCI) as a promising tumor-associated antigen, is
broadly over-expressed in most cancer types, and plays an essential
role in antagonizing cell death, supporting tumor-associated
angiogenesis, and promoting resistance to anti-cancer therapies.
Immunovaccine has identified over 15 cancer indications in which
the over-expression of survivin can be targeted by DPX-Survivac.
DPX-Survivac received Fast Track designation from the U.S. Food
& Drug Administration (FDA) as maintenance therapy in advanced
ovarian cancer, as well as orphan drug designation status from the
U.S. FDA and the European Medicines Agency (EMA) in the ovarian
cancer indication.
About ImmunovaccineImmunovaccine is a
clinical-stage biopharmaceutical company dedicated to making
immunotherapy more effective, more broadly applicable, and more
widely available to people facing cancer and infectious diseases.
Immunovaccine is developing T cell-activating cancer
immunotherapies based on its patented immuno-stimulating technology
platform, which provides controlled and prolonged delivery of
immuno-stimulating agents to the immune system.
Immunovaccine has advanced two T cell activation therapies for
cancer through phase 1 human clinical trials, and is currently
conducting multiple phase 1b and phase 2 studies with Incyte Corp.
and Merck. These studies are assessing lead candidate,
DPX-Survivac, as a combination therapy in ovarian cancer and
diffuse large B cell lymphoma. The
Corporation is also exploring additional applications of its
platform for infectious diseases and other therapeutic areas.
DPX-RSV is an innovative vaccine candidate for respiratory
syncytial virus (RSV), which has recently completed a Phase 1
clinical trial. Connect at www.imvaccine.com
Immunovaccine Forward-Looking StatementsThis
press release contains forward-looking information under applicable
securities law. All information that addresses activities or
developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Company, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law.
Contacts for Immunovaccine:
MEDIA Mike Beyer, Sam Brown
Inc.T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONSPierre Labbé, Chief
Financial OfficerT: (902) 492-1819 E:
info@imvaccine.com
Patti Bank, Managing Director, Westwicke
PartnersO: (415) 513-1284T: (415) 515-4572 E:
patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024